WXXWY Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals has a net margin of -- compared to WuXi Biologics (Cayman)'s net margin of -107.73%. WuXi Biologics (Cayman)'s return on equity of 6.19% beat CASI Pharmaceuticals's return on equity of -137%.

WuXi Biologics (Cayman) has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 95.44%. Given that CASI Pharmaceuticals has higher upside potential than WuXi Biologics (Cayman), analysts believe CASI Pharmaceuticals is more attractive than WuXi Biologics (Cayman).

WuXi Biologics (Cayman) has a beta of 0.434, which suggesting that the stock is 56.625% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.577%.

WuXi Biologics (Cayman) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman) pays -- of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.

WuXi Biologics (Cayman) quarterly revenues are --, which are smaller than CASI Pharmaceuticals quarterly revenues of $7.8M. WuXi Biologics (Cayman)'s net income of -- is lower than CASI Pharmaceuticals's net income of -$8.4M. Notably, WuXi Biologics (Cayman)'s price-to-earnings ratio is 26.86x while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman) is 4.05x versus 1.93x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -- compared to WuXi Biologics (Cayman)'s net margin of -101.61%. WuXi Biologics (Cayman)'s return on equity of 6.19% beat China Pharma Holding's return on equity of -66.27%.

WuXi Biologics (Cayman) has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman) has higher upside potential than China Pharma Holding, analysts believe WuXi Biologics (Cayman) is more attractive than China Pharma Holding.

WuXi Biologics (Cayman) has a beta of 0.434, which suggesting that the stock is 56.625% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.874%.

WuXi Biologics (Cayman) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman) pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

WuXi Biologics (Cayman) quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. WuXi Biologics (Cayman)'s net income of -- is lower than China Pharma Holding's net income of -$1.1M. Notably, WuXi Biologics (Cayman)'s price-to-earnings ratio is 26.86x while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman) is 4.05x versus 0.54x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to WuXi Biologics (Cayman)'s net margin of --. WuXi Biologics (Cayman)'s return on equity of 6.19% beat Sinovac Biotech's return on equity of -1.05%.

WuXi Biologics (Cayman) has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman) has higher upside potential than Sinovac Biotech, analysts believe WuXi Biologics (Cayman) is more attractive than Sinovac Biotech.

WuXi Biologics (Cayman) has a beta of 0.434, which suggesting that the stock is 56.625% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

WuXi Biologics (Cayman) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman) pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

WuXi Biologics (Cayman) quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. WuXi Biologics (Cayman)'s net income of -- is lower than Sinovac Biotech's net income of --. Notably, WuXi Biologics (Cayman)'s price-to-earnings ratio is 26.86x while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman) is 4.05x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to WuXi Biologics (Cayman)'s net margin of -40.75%. WuXi Biologics (Cayman)'s return on equity of 6.19% beat Zai Lab's return on equity of -35.53%.

WuXi Biologics (Cayman) has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 94.84%. Given that Zai Lab has higher upside potential than WuXi Biologics (Cayman), analysts believe Zai Lab is more attractive than WuXi Biologics (Cayman).

WuXi Biologics (Cayman) has a beta of 0.434, which suggesting that the stock is 56.625% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.

WuXi Biologics (Cayman) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman) pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

WuXi Biologics (Cayman) quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $102.3M. WuXi Biologics (Cayman)'s net income of -- is lower than Zai Lab's net income of -$41.7M. Notably, WuXi Biologics (Cayman)'s price-to-earnings ratio is 26.86x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman) is 4.05x versus 7.37x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.